Humacyte Inc. (NASDAQ: HUMA) stock fell 22.76% to $1.03 on Thursday despite reporting positive interim Phase 3 data for its acellular tissue-engineered vessel (ATEV), as investors focused on a heavily dilutive stock offering announced alongside the clinical update. The company priced an underwritten public offering of 47,619,048 shares of common stock at a public offering price of $1.05 per share to raise aggregate gross proceeds of $50 million. The offering, expected to close on or about June 12, 2026, aims to secure capital for the commercialization of its FDA-approved product, Symvess, and other corporate activities. The company has granted underwriters a 30-day option to purchase up to an additional 7,142,857 shares at the public offering price, less underwriting discounts and commissions.

Phase 3 Trial Meets Primary Endpoint

Humacyte released interim Phase 3 results for its ATEV in female dialysis patients. A prespecified interim analysis of the first 80 patients enrolled in its Phase 3 V012 study met the trial's primary endpoint. Patients treated with the ATEV recorded an average of 220 catheter-free days, compared with 129 days for those receiving an autologous arteriovenous (AV) fistula, the current standard of care. The 91-day improvement was statistically significant, with a p-value of 0.00070.

Safety Profile and Next Steps

Patients receiving the ATEV experienced infections at a rate of six per 100 patient-years, compared with 23 per 100 patient-years among patients receiving AV fistulas. No access-related infections were reported among ATEV recipients, while three occurred in the AV fistula group. Researchers reported no spontaneous ruptures in either treatment arm and said no new or unexpected safety concerns emerged during the analysis. Under the study protocol, enrollment will now end early after the primary endpoint is achieved, while enrolled patients will continue to be monitored. Humacyte plans to submit a supplemental Biologics License Application to the FDA in the second half of 2026.

Use of Proceeds

The net proceeds from the offering are designated for several strategic areas. Primary allocations include funding the commercialization of Symvess and the planned filing of a Biologics License Application supplement for a hemodialysis indication. Funds will also support the development of product candidates in the pipeline, as well as working capital and general corporate purposes.

Regulatory and Filing Details

A shelf registration statement on Form S-3 (No. 333-290231) was filed with the Securities and Exchange Commission (SEC) on September 12, 2025, and declared effective on September 22, 2025. A preliminary prospectus supplement and accompanying prospectus were filed with the SEC on June 10, 2026. The final prospectus supplement will be available on the SEC's website upon filing.

Underwriting and Contact Information

Barclays, BTIG, and Titan Partners, a division of American Capital Partners, are acting as joint book-running managers for the offering. Copies of the final prospectus supplement and accompanying prospectus can be obtained from the underwriters upon availability.